# Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

> **NCT01266447** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Small Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Recurrent Cervical Carcinoma
- Stage III Cervical Cancer
- Stage IVA Cervical Cancer
- Stage IVB Cervical Cancer

## Interventions

- **BIOLOGICAL:** Filgrastim
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pegfilgrastim
- **DRUG:** Topotecan Hydrochloride
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01266447
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01266447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01266447, "Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01266447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*